SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs earnings beat and stronger outlook, driven by surging AI data-center demand, have fueled a sharp rally and renewed optimism that AI spending is translating into revenue. Traders are also debating whether the gains can hold, citing valuation, weaker cash flow and gaming results, and the risk of AMD becoming more dependent on data-center growth.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros quarterly results topped expectations and its revenue outlook was raised on strong AI-server demand, drawing bullish calls for a rerating and praise for the new CFO. Traders are frustrated by the muted share-price response, while skeptics point to thin margins, cash-flow and inventory concerns, and lingering doubts about management and credibility.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

A letter from 28 HOPE-3 investigators urging FDA approval of deramiocel has renewed optimism ahead of the November 22 decision for Capricors Duchenne muscular dystrophy therapy. Traders are also debating the FDAs prior concerns about the trial data and speculating that short covering is amplifying the move; approval remains uncertain.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Aristas quarterly results beat expectations and its next-quarter guidance came in well above consensus, with traders pointing to strong AI-networking demand as the catalyst for the stocks rally. The reaction is broadly bullish, though some traders warn that elevated valuation and volatile trading could bring profit-taking.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas is drawing attention after a Q3 earnings beat and stronger Q4 guidance, with its AI infrastructure growth and Nvidia-related 800V power work adding to the bullish case. Traders remain divided: bulls see traction in the AI data-center pivot, while skeptics question whether the partnerships will translate into sizable customer orders and note ongoing losses.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

AMDs strong earnings and upbeat outlook have renewed optimism that AI-chip demand remains robust, with traders debating whether the results will lift Nvidia or sharpen competition; others remain cautious about AI spending, valuations, and Nvidias difficulty sustaining its rebound.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs quarterly results beat expectations and its raised outlook reinforced optimism around AI data-center connectivity demand, but shares sold off despite the strong report. Traders are debating whether the reaction reflects sell-the-news profit-taking and a premium valuation or an opportunity to buy into continued growth.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

U.S. midterm election outcomes dominate discussion, with traders debating whether Democratic gains would weaken Trumps political position and pressure DJT or whether Republican results could support a rally. The stocks political ties are central to the debate, while reactions range from bullish election-driven bounce expectations to bearish selloff calls.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is drawing attention after quarterly results came in ahead of expectations and the company raised its revenue guidance. Bullish traders point to continued growth and its lidar and robotics opportunities, while others remain wary of ongoing losses and volatile price action.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingos quarterly results are driving attention: user growth accelerated, revenue and bookings topped expectations, and the company raised its outlook, while earnings per share missed. Traders are split over whether strong engagement and guidance outweigh concerns about profitability, valuation, and AI competition; shares have been volatile despite bullish reactions to the growth metrics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the...

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences Citius Pharmaceuticals to Participate in October 2026 Investor ConferencesPR NewswireCRANFORD, N.J., Oct. 12, 2026Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth...

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences Citius Pharmaceuticals to Participate in September 2026 Investor Conferences PR Newswire CRANFORD, N.J., Sept. 3, 2026 Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright...

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 14, 2026 $7.1 Million in revenue for the first...

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 14, 2026 $7.1 million in revenue for the first nine months...

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri PR Newswire CRANFORD, N.J., Aug. 12, 2026 CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology...

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment PR Newswire CRANFORD, N.J., Aug. 5, 2026 New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal...

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption PR Newswire CRANFORD, N.J., July 21, 2026 Expanded...

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin...

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR...

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Citius Oncology Inc.

Citius Oncology Launches Lymphir In US For Skin Cancer — Retail Traders Eye Major Upside

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>FDA approved Lymphir for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma.</li><li>Phase 3 data showed a 36.2% response rate, with most patients seeing reduced skin tumor burden.</li><li>Lymphir is available nationwide with a permanent J-code effective April to support reimbursement.</li></ul>Citius Oncology (CTOR) said on Monday it has launched&nbsp;Lymphir, a newly approved cancer immunotherapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL), making the drug available nationwide through specialty distributors.The U.S. Food and Drug Administration (FDA) approved Lymphir, also known as denileukin diftitox-cxdlfor adults with cutaneous T-cell lymphoma, a form of skin cancer that can cause painful, itchy lesions. The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting regulatory T cells.The stock jumped nearly 18% to $1.62 at the time of writing.&nbsp;<h2 class="st-heading-2">Clinical Findings</h2>The immunotherapy approval was supported by results from Phase 3 Study 302, which reported an objective response rate of 36.2%. According to Citius, 84% of evaluable patients saw reductions in skin tumor burden, and the median time to response was 1.4 months. The company said the therapy was not associated with cumulative toxicity.Lymphir is the first FDA-approved systemic therapy for CTCL in more than seven years. It has been added to the National Comprehensive Cancer Network guidelines with a Category 2A recommendation, meaning the therapy is recommended, with uniform agreement from experts.&nbsp;<h2 class="st-heading-2">Commercial Rollout&nbsp;</h2>Lymphir has a permanent J-code, effective since April, to support reimbursement. Citius is providing medical education, payer-access support and a patient assistance program, which includes reimbursement and benefits guidance as well as prior authorization support.&nbsp;<h2 class="st-heading-2">Global Expansion Plans&nbsp;</h2>Outside the U.S., Citius holds rights to develop and commercialize Lymphir in all markets except India, Japan and certain parts of Asia. The company recently signed a distribution agreement with Integris Pharma to begin named-patient access programs in Greece, Cyprus and other Southern European and Balkan countries.<h2 class="st-heading-2">Stocktwits Users Turn ‘Extremely Bullish’</h2>On Stocktwits, retail sentiment for Citius Oncology turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:969/142;" src="https://news.stocktwits-cdn.com/ctor_ss_png_c597304fdc.webp" alt="ctor ss.png" width="969" height="142"><figcaption>CTOR sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure>One bullish user said, “interesting to see what happens here - back on the scanner!”<stembedurl>https://stocktwits.com/JammyGitTradaz/message/637812831</stembedurl>Another user suggested the stock could return to $5.&nbsp;<stembedurl>https://stocktwits.com/CookieWatcher/message/637811657</stembedurl><a href="https://stocktwits.com/symbol/CTOR">CTOR stock</a> rose nearly 43% so far this year.&nbsp;Get updates to this developing story directly on Stocktwits.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Citius Oncology stock (CTOR) jumped nearly 14% at the time of writing.  (Photo credit: Getty Images)

The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting regulatory T cells.

Republicans keep both chambers

Republicans keep the House, lose the Senate

Republicans keep the Senate, lose the House

Democrats win both chambers

Stocktwits

Stocktwits Polls

$CTOR communicates a 120% surge in LYMPHIR shipments to U.S. wholesalers in Q4 2026, with institutional demand rising.

jorge .miguel

$CTOR Let's see 91.75 millions shares at this price, what maybe a 4:1 reverse split coming.  Dilute it down so it takes two years to reach the rock bottom price of a quarter?  This stock is junk, just like CTXR.

Brian Blake

$CTOR When is the reverse split going to be announced?  Following CTXRs shareholder treatment I see.

$CTOR  
 
What is the interest in CTOR today? 
 
Is it a delayed reaction to the 10/26/2026 PR, or are they just drunk--LOL.

m. bman

$CTOR Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

MomentumScalper

$CTOR Regained compliance then promptly dropped back under a buck. This company barely hangs on by threads over the years. Unreal.

Feed

News

Sentiment

Fundamentals

Info

CTOR Citius Oncology Inc.

Fundamentals

Latest CTOR News